What Is Compounded Tirzepatide and Is It Still Legal?

Compounded tirzepatide is a tirzepatide injection prepared by a licensed compounding pharmacy rather than manufactured by Eli Lilly and Company. It uses the same active molecule found in Zepbound and Mounjaro, but the finished product is not FDA-approved, is usually combined with an additive like vitamin B12, and is produced under a different regulatory pathway. That pathway narrowed sharply after the FDA reaffirmed the tirzepatide shortage resolved in December 2024 and a federal court denied a preliminary injunction on March 5, 2025, closing the door that 503A and 503B compounders had been pouring through for over two years.¹

This guide covers what compounded tirzepatide is, how it differs from Zepbound and Mounjaro, why compounding pharmacies ever made it in the first place, what the March 2025 FDA ruling changed, and what current safety data actually shows. It does not cover pricing strategy (see our tirzepatide cost guide for that), individual dosing decisions, or provider-specific recommendations. Clinical decisions about GLP-1 therapy should be made with a licensed prescriber.

What is compounded tirzepatide?

Tirzepatide is a once-weekly injectable peptide that acts on two receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual-agonist mechanism is what distinguishes it from semaglutide, which targets GLP-1 alone. In the SURMOUNT-1 trial, adults with obesity who took tirzepatide 15 mg once weekly for 72 weeks lost an average of 22.5% of body weight, and 57% achieved at least 20% weight reduction.²

Eli Lilly and Company holds the patents on tirzepatide and markets it under two brand names: Mounjaro (approved for Type 2 diabetes in May 2022) and Zepbound (approved for chronic weight management in November 2023, with an additional approval for obstructive sleep apnea in adults with obesity in December 2024). Both products are manufactured by Eli Lilly at FDA-regulated facilities and sold as either prefilled autoinjector pens or single-dose vials.

Compounded tirzepatide is a different animal. A compounding pharmacy buys the active pharmaceutical ingredient from an FDA-registered bulk-drug-substance supplier, then prepares a finished injectable product on its own premises. Two categories of compounding pharmacy operate in the US:

• 503A pharmacies are state-licensed compounders that prepare medications for individual, patient-specific prescriptions. They are not FDA-registered and do not file new drug applications.
• 503B outsourcing facilities are FDA-registered compounders allowed to produce larger batches without patient-specific prescriptions, under tighter federal oversight than 503A pharmacies.

Neither category submits its finished tirzepatide product for FDA review. That is the structural difference between "compounded tirzepatide" and "tirzepatide" as sold by Eli Lilly.¹

How is compounded tirzepatide different from Zepbound and Mounjaro?

The active molecule is the same. Almost everything else is different. Here is the comparison, head-to-head:

Comparison as of April 20, 2026. Pricing figures for compounded products vary widely by provider and are included for directional context only; confirm any price directly with the provider.

Two dimensions in that table do most of the work. The first is FDA approval of the finished product: Zepbound and Mounjaro go through the full drug-approval process, including Chemistry, Manufacturing, and Controls review of every excipient, every container, and every batch. Compounded tirzepatide does not. The second is additives: a compounded product is rarely just tirzepatide. It is often tirzepatide combined with something else, which is the basis on which some pharmacies argue it is not "essentially a copy" of Zepbound or Mounjaro.⁵

Why did pharmacies start making compounded tirzepatide?

Tirzepatide entered the FDA drug shortage list in late 2022, soon after Mounjaro's approval, as demand for GLP-1 therapies outstripped Eli Lilly's manufacturing capacity. Federal law permits compounding pharmacies to prepare copies of an FDA-approved drug when that drug is on the shortage list, under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The shortage listing unlocked a legal pathway, and a cottage industry of telehealth providers paired with 503A and 503B compounding pharmacies to fill the gap.¹

By early 2024 the drug was available through dozens of online clinics at prices well below Eli Lilly's list price, often bundled into monthly telehealth memberships. The pricing gap was large enough that even some patients with commercial insurance chose compounded products over the brand drug. That is the market the FDA's 2024 and 2025 actions reshaped.

Is compounded tirzepatide still legal after the March 2025 FDA ruling?

In October 2024, the FDA initially removed tirzepatide from the drug shortage list. After industry challenges, the agency reconsidered, then reaffirmed the shortage resolved in a declaratory order dated December 19, 2024. The order gave compounders a transition window: 60 days for 503A pharmacies and 90 days for 503B outsourcing facilities to stop producing copies of tirzepatide.⁶

The Outsourcing Facilities Association challenged the order in federal court. On March 5, 2025, the US District Court for the Northern District of Texas denied the association's motion for a preliminary injunction, leaving the FDA's transition deadlines intact. The 503A window closed days later; the 503B window closed March 19, 2025. After those dates, state-licensed pharmacies and outsourcing facilities could no longer lawfully compound copies of tirzepatide under the shortage exception.¹

The FDA has followed up its December 2024 order with warning letters. In September 2025, the agency issued warning letters to three facilities, EA WORKS LLC dba Trust Labs, GenLabMeds, and GLP-1 Solution, for compounding, distributing, or marketing tirzepatide or semaglutide products without valid regulatory pathways.⁷ More enforcement actions are likely.

Is compounded tirzepatide safe?

Three data sources shape the 2026 safety picture: FDA adverse-event reports, Eli Lilly's testing of compounded samples, and a March 2026 Lilly open letter flagging a novel impurity.

FDA adverse-event reports

As of February 28, 2025, the FDA had received more than 320 reports of adverse events tied to compounded tirzepatide, and more than 455 reports tied to compounded semaglutide. Adverse-event reports are not proof of causation, they are signals that warrant investigation, but the volume is notable given that the compounded market is a small share of total GLP-1 prescriptions.³

Lilly testing of compounded samples

Eli Lilly has tested compounded samples purchased from the market and published aggregate results. The company reports that roughly half of the knockoff tirzepatide it tested had potency below the amount listed on the label, and some samples contained no tirzepatide at all. Additional findings included bacterial contamination, high endotoxin levels, and high levels of chemical impurities.⁴

The March 2026 B12 impurity finding

On March 12, 2026, Eli Lilly published an open letter describing a previously undocumented chemical impurity that forms when tirzepatide is combined with vitamin B12 (methylcobalamin, hydroxocobalamin, or cyanocobalamin). Lilly's position is that the short- and long-term effects of this impurity in humans are unknown, including its effects on receptor binding, toxicity, immune reactions, and pharmacokinetics. A pre-print manuscript posted to medRxiv the same week describes the underlying chemistry in more detail.⁵⁸

These three strands do not mean every compounded product is dangerous. They do mean the safety profile of a specific compounded product depends heavily on the pharmacy that prepared it, the additives in the formulation, and the batch-level testing that pharmacy performs. None of those variables are uniform across providers.

What should you ask before ordering compounded tirzepatide?

If you are considering compounded tirzepatide, these six questions will separate pharmacies that operate within defensible regulatory lines from those that do not. Take this list to any prescriber or telehealth intake before paying for a month's supply.

1. Which specific compounding pharmacy prepares your tirzepatide, and in which state? A reputable provider will name the pharmacy. Verify the pharmacy's current license on that state's board of pharmacy registry.
2. Is the pharmacy a 503A state-licensed pharmacy or a 503B outsourcing facility? For 503B, confirm registration directly on the FDA's public list of registered outsourcing facilities.
3. What is the exact formulation? Tirzepatide alone, or tirzepatide plus B12, glycine, pyridoxine, or another additive? The additive is often the regulatory hook the pharmacy relies on.
4. Is the product prepared patient-specific under a valid prescription? 503A compounding is supposed to be patient-specific. Mass-produced 503A "stock" is a compliance red flag.
5. Will the pharmacy provide a Certificate of Analysis for the batch you receive? A CoA should show potency and sterility results from an independent lab. Many reputable compounders publish CoAs; many do not.
6. What happens if the FDA takes enforcement action against this specific product or pharmacy? Refund policy, prescription continuity, and transition to an FDA-approved alternative should be spelled out before you pay, not after.

Frequently Asked Questions

What is compounded tirzepatide?

Compounded tirzepatide is a tirzepatide injection prepared by a licensed compounding pharmacy rather than manufactured by Eli Lilly and Company. The active drug is the same dual GIP and GLP-1 receptor agonist found in Zepbound and Mounjaro, but the finished product is not FDA-approved, is typically combined with an additive like vitamin B12 or glycine, and is made under a different regulatory pathway for patient-specific compounding.

Is compounded tirzepatide still legal in 2026?

The shortage-era enforcement-discretion window closed after the FDA reaffirmed tirzepatide's shortage resolved in December 2024 and a federal court denied a preliminary injunction on March 5, 2025. State-licensed (503A) and outsourcing (503B) facilities can no longer produce copies of Zepbound or Mounjaro. Some pharmacies still compound tirzepatide with additives under a personalization theory, which remains contested.

Is compounded tirzepatide the same as Zepbound?

No. Compounded tirzepatide and Zepbound share the same active molecule but differ in manufacturer, regulatory status, and formulation. Zepbound is made by Eli Lilly to FDA-approved specifications. Compounded tirzepatide is made by a compounding pharmacy, is not FDA-approved, and typically contains additives such as B12, glycine, or pyridoxine. Eli Lilly testing reported roughly half of compounded samples tested had potency below the labeled amount.

Is compounded tirzepatide safe?

The FDA had received more than 320 adverse-event reports tied to compounded tirzepatide as of February 28, 2025. Eli Lilly testing of market samples found bacteria, high endotoxins, impurities, and potency below label in a substantial share. A March 2026 Lilly open letter flagged a novel tirzepatide-B12 impurity whose effects in humans are unknown.

Why is compounded tirzepatide cheaper than Zepbound?

Compounded tirzepatide is cheaper primarily because it is not FDA-approved and does not carry the research, manufacturing, and distribution costs Eli Lilly built into Zepbound and Mounjaro pricing. Compounding pharmacies source the active ingredient from FDA-registered bulk drug substance suppliers and prepare the injection at smaller scale. The trade-off is the absence of FDA review of the finished product and the safety considerations that follow.

How do I verify a compounding pharmacy before ordering?

Confirm the pharmacy's current license on the state board of pharmacy registry where you receive the medication. For outsourcing facilities, confirm 503B registration on the FDA's public list. Ask whether the product is prepared patient-specific, what additives are in it, and whether the pharmacy publishes a batch-level Certificate of Analysis showing potency and sterility results.

The Bottom Line

Compounded tirzepatide is a category, not a single product. It is any tirzepatide injection prepared by a licensed compounding pharmacy rather than manufactured by Eli Lilly, and the finished product is not FDA-approved. The shortage-era pathway that let 503A and 503B facilities make copies of Zepbound and Mounjaro closed after the March 5, 2025 federal court ruling. What remains is a narrower market of pharmacies compounding tirzepatide combined with additives like B12 or glycine under a personalization theory that Eli Lilly and the FDA are actively challenging.

For any specific patient, the question is not whether compounded tirzepatide is categorically good or bad. It is whether the specific pharmacy, specific formulation, and specific regulatory posture behind a product are transparent enough to evaluate, and whether the pricing gap against LillyDirect Zepbound vials at $299 to $699 per month is large enough to justify the variability in safety and legal standing. For the full pricing breakdown across brand, self-pay, insurance, and compounded paths, see our tirzepatide cost guide.